These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 328135)

  • 1. Pharmacokinetics: selectivity of action related to physicochemical properties and kinetic patterns of anticancer drugs.
    Nichol CA
    Cancer; 1977 Jul; 40(1 Suppl):519-28. PubMed ID: 328135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate resistance and uptake of DDMP by L5178Y cells. Selective protection with folinic acid.
    Hill BT; Price LA; Goldie JH; Harrison SI
    Eur J Cancer (1965); 1975 Aug; 11(8):545-53. PubMed ID: 1083340
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.
    Nichol CA; Cavallito JC; Woolley JL; Sigel CW
    Cancer Treat Rep; 1977 Jul; 61(4):559-64. PubMed ID: 301777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichloromethotrexate--a critical reassessment.
    O'Dwyer PJ; Leyland-Jones B; Alonso MT; Eisenberger M; Hoth DF
    J Clin Oncol; 1985 Aug; 3(8):1148-53. PubMed ID: 4020413
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake.
    Taylor IW; Slowiaczek P; Friedlander ML; Tattersall MH
    Cancer Res; 1985 Mar; 45(3):978-82. PubMed ID: 3971388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.
    Mellett LB
    Cancer Treat Rep; 1977 Jul; 61(4):527-31. PubMed ID: 884690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antifolates in clinical development.
    Takimoto CH; Allegra CJ
    Oncology (Williston Park); 1995 Jul; 9(7):649-56, 659 DISC 660, 662, 665. PubMed ID: 8924375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of network thermodynamics to the computer modeling of the pharmacology of anticancer agents: a network model for methotrexate action as a comprehensive example.
    White JC; Mikulecky DC
    Pharmacol Ther; 1981; 15(2):251-91. PubMed ID: 7045894
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
    Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
    Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
    Goldman ID; Matherly LH
    NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amethopterin metabolism in mammalian cells].
    Balińska M
    Postepy Biochem; 1988; 34(4):417-27. PubMed ID: 2479942
    [No Abstract]   [Full Text] [Related]  

  • 13. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
    Sharma RC; Assaraf YG; Schimke RT
    Cancer Res; 1991 Jun; 51(11):2949-59. PubMed ID: 1674447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quantitative analysis of cell-kill effects of anticancer drugs: consideration of both in vitro and in vivo experimental systems].
    Sugiyama Y; Kobayashi T; Inaba M
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3183-98. PubMed ID: 3318699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice.
    Wright JE; Pardo M; Tretyakov A; Alperin WL; Trites D; Rosowsky A
    Cancer Chemother Pharmacol; 1998; 42(4):300-6. PubMed ID: 9744775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of folate-related drug targets in cancer treatment.
    Robien K; Boynton A; Ulrich CM
    Pharmacogenomics; 2005 Oct; 6(7):673-89. PubMed ID: 16207145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
    Sirotnak FM; Wendel HG; Bornmann WG; Tong WP; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Sep; 6(9):3705-12. PubMed ID: 10999764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations.
    Blasberg RG; Groothuis DR
    Semin Oncol; 1986 Mar; 13(1):70-82. PubMed ID: 3513317
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple basis of combination chemotherapy.
    Mihich E; Grindey GB
    Cancer; 1977 Jul; 40(1 Suppl):534-43. PubMed ID: 328136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
    Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.